news
FDA approves Phase III trial of synthetic biological COVID-19 treatment
The international Phase III trial will evaluate whether a 14 day course of carrimycin can improve outcomes for COVID-19 patients with severe symptoms.
List view / Grid view
bacterial infections
news
Collaboration to develop the world’s first prophylactic gonorrhoea vaccine
Therapyx and Intravacc will jointly develop NGoXIM, a microsphere vaccine which is designed to stimulate adaptive immunity against gonorrhoea.
news
Avet recalls tetracycline HCl capsules to consumer level
The company announced the voluntary recall is due to low, out of specification dissolution test results in specific batches of its tetracycline products.
news
‘Cocktail’ of pharmaceuticals identified in Bangladeshi waters
A study of both city and rural water sources identified antimicrobials at every site and suggests the contamination could be causing the emergence of treatment-resistant microbes.
article
Exploring the latest developments in biomedical materials
Drug Target Review rounds up some of the latest developments in materials developed for medical applications, including hydrogels, implants and more.
news
Committee for Medicinal Products for Human Use (CHMP) meeting highlights
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
article
Does the antibacterial pipeline sufficiently target WHO priority pathogens?
A WHO review has concluded that while innovative therapies have been developed for TB and C. diff, other priority pathogens are likely to develop resistance to future therapies.
news
Colour-changing bandages can release antibiotics and prevent resistant microbes
Research has developed bandages which change colour and release antibiotics and/or reactive oxygen species in response to an infected wound which could curb the spread of antibiotic resistance.
news
Expansion of the global antibiotics market size
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
